Table 4. Associations with SNPs at the novel 17q21 region with ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
| SNP, Allele1/Allele2 | BRCA1 (Stage 1 & 2 samples) | BRCA2 | BRCA1 & BRCA2 samples combined | ||||||
| Unaffected (All2 freq) | Ovarian Cancer (All2 freq) | HR* (95%CI) | P-trend | Unaffected (All2 freq) | Ovarian Cancer (All2 freq) | HR* (95%CI) | P-trend | P-trend | |
| rs17631303, A/G | 9793 (0.19) | 1831 (0.22) | 1.27 (1.16–1.40) | 3.04×10−7 | 7481 (0.19) | 626 (0.24) | 1.32 (1.15–1.52) | 1.98×10−4 | 2.80×10−10 |
| rs2077606, G/A | 9736 (0.19) | 1810 (0.22) | 1.27 (1.15–1.40) | 5.51×10−7 | 7421 (0.19) | 613 (0.23) | 1.31 (1.13–1.50) | 5.60×10−4 | 1.27×10−9 |
| rs2532348, A/G | 9511 (0.21) | 1789 (0.24) | 1.25 (1.14–1.37) | 8.71×10−7 | 7407 (0.23) | 615 (0.28) | 1.33 (1.17–1.51) | 4.62×10−5 | 2.49×10−10 |
| rs183211, G/A | 9866 (0.23) | 1839 (0.26) | 1.25 (1.15–1.37) | 5.67×10−7 | 7580 (0.25) | 631 (0.30) | 1.26 (1.11–1.43) | 9.26×10−4 | 2.01×10−9 |
| rs169201, A/G | 9865 (0.20) | 1839 (0.23) | 1.27 (1.15–1.37) | 5.04×10−7 | 7578 (0.21) | 631 (0.26) | 1.36 (1.19–1.55) | 1.72×10−5 | 6.24×10−11 |
| rs199443, G/A | 9849 (0.20) | 1835 (0.23) | 1.26 (1.15–1.39) | 5.15×10−7 | 7580 (0.21) | 631 (0.26) | 1.35 (1.18–1.54) | 2.57×10−5 | 8.87×10−11 |
| rs199534, A/C | 9865 (0.20) | 1839 (0.23) | 1.26 (1.15–1.39) | 6.26×10−7 | 7575 (0.21) | 630 (0.26) | 1.35 (1.18–1.55) | 1.90×10−5 | 8.57×10−11 |
*
HRs estimated under the single disease risk model.